Symptomatic treatment of ALS
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Patients with symptoms suggestive of a progressive neurologic disease, such as amyotrophic lateral sclerosis (ALS), usually seek an initial medical consult to obtain a diagnosis, although their primary goal is ultimately to obtain some form of treatment that will ameliorate their condition. However, physicians can easily become focused on the etiologic aspects of the disorder in the pursuit of a definitive diagnosis. Patients respond by becoming preoccupied with the clinical significance of specific clinical and laboratory findings and determining how these relate to the pathophysiology of the disease. Therefore, it is often necessary for both the physician and the patient to shift their focus of attention away from diagnostic issues and to concentrate their efforts on identifying the interventions that will best lessen disease progression and/or provide symptomatic relief.
Two types of treatment options are available for patients with ALS: those that are disease-specific and those that are patient-specific. As discussed in detail elsewhere in this issue, there is an expanding armamentarium of potentially useful pharmacologic agents for the treatment of ALS. Riluzole, a glutamate antagonist, is the only agent approved for the treatment of ALS. Others (e.g., other glutamate inhibitors, neurotrophic factors) are now undergoing clinical trials or are being used on an experimental basis. Although at present there is no cure for ALS, a drug such as riluzole has been shown to slow disease progression and improve survival outcomes. [1,2] Disease-specific therapies are only one aspect of an overall management program for ALS. Many symptomatic treatments designed to enhance the patient's overall quality of life by mitigating the complications of ALS and enhancing patient comfort provide an equally important dimension of patient care.
This article discusses the approaches now in use to manage some of the most common symptoms of ALS, including the following: impaired speech and other …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Special Article
Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review)Report of the Quality Standards Subcommittee of the American Academy of NeurologyR. G. Miller, C. E. Jackson, E. J. Kasarskis et al.Neurology, October 12, 2009 -
Articles
Patient and caregiver communications and decisionsDeborah Gelinas et al.Neurology, April 01, 1997 -
Articles
Patient-ventilator asynchrony with nocturnal noninvasive ventilation in ALSA.D. Atkeson, A. RoyChoudhury, G. Harrington-Moroney et al.Neurology, July 27, 2011 -
Article
Trial of early noninvasive ventilation for ALSA pilot placebo-controlled studyTeresa L. Jacobs, Devin L. Brown, Jonggyu Baek et al.Neurology, August 31, 2016